Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 3
1991 3
1992 2
1993 1
1994 5
1995 1
1996 4
1997 6
1998 2
1999 3
2000 2
2002 1
2003 2
2004 7
2005 3
2006 4
2007 11
2008 8
2009 11
2010 6
2011 8
2012 13
2013 9
2014 11
2015 15
2016 5
2017 14
2018 8
2019 16
2020 10
2021 10
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review.
Rajagopal S, Yao X, Abadir W, Baetz TD, Easson A, Knight G, McWhirter E, Nessim C, Rosen CF, Sun A, Wright FC, Petrella TM. Rajagopal S, et al. Among authors: petrella tm. Surg Oncol. 2024 Apr 10;54:102077. doi: 10.1016/j.suronc.2024.102077. Online ahead of print. Surg Oncol. 2024. PMID: 38657486 Free article. Review.
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent.
Rajagopal S, Yao X, Abadir W, Baetz TD, Easson AM, Knight G, McWhirter E, Nessim C, Rosen CF, Sun A, Wright FC, Petrella TM. Rajagopal S, et al. Among authors: petrella tm. Clin Oncol (R Coll Radiol). 2024 Apr;36(4):243-253. doi: 10.1016/j.clon.2024.01.012. Epub 2024 Jan 20. Clin Oncol (R Coll Radiol). 2024. PMID: 38336503
A tailored approach to horizon scanning for cancer medicines.
Soon JA, To YH, Alexander M, Trapani K, Ascierto PA, Athan S, Brown MP, Burge M, Haydon A, Hughes B, Itchins M, John T, Kao S, Koopman M, Li BT, Long GV, Loree JM, Markman B, Meniawy TM, Menzies AM, Nott L, Pavlakis N, Petrella TM, Popat S, Tie J, Xu W, Yip D, Zalcberg J, Solomon BJ, Gibbs P, McArthur GA, Franchini F, IJzerman M. Soon JA, et al. Among authors: petrella tm. J Cancer Policy. 2023 Dec;38:100441. doi: 10.1016/j.jcpo.2023.100441. Epub 2023 Nov 20. J Cancer Policy. 2023. PMID: 38008488 Free article.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Robert C, et al. Among authors: petrella tm. J Clin Oncol. 2023 Aug 20;41(24):3998-4003. doi: 10.1200/JCO.22.01599. Epub 2023 Jun 22. J Clin Oncol. 2023. PMID: 37348035
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV. Arance A, et al. Among authors: petrella tm. J Clin Oncol. 2023 Jan 1;41(1):75-85. doi: 10.1200/JCO.22.00221. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867951 Clinical Trial.
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Rajkumar S, et al. Among authors: petrella t. Cell Rep. 2022 Apr 5;39(1):110634. doi: 10.1016/j.celrep.2022.110634. Cell Rep. 2022. PMID: 35385748 Free article.
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop.
Kempf W, Petrella T, Willemze R, Jansen P, Berti E, Santucci M, Geissinger E, Cerroni L, Maubec E, Battistella M, Goodlad J, Guenova E, Lappalainen K, Ranki A, Craig P, Calonje E, Martin B, Whittaker S, Oschlies I, Wehkamp U, Nicolay JP, Wobser M, Scarisbruck J, Pimpinelli N, Stadler R, Kerl French K, Quaglino P, Lin J, Chen L, Beer M, Emanuel P, Dalle S, Robson A. Kempf W, et al. Among authors: petrella t. Br J Dermatol. 2022 May;186(5):887-897. doi: 10.1111/bjd.20973. Br J Dermatol. 2022. PMID: 34988968
194 results